title: Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia?
abstract: To assess the clinical significance of AML1/ETO gene detected by nested reverse transcriptase polymerase chain reaction, the outcome of 7 patients with acute myeloblastic leukemia between 3 and 14 years of age were presented. All patients had complete remission (CR) at the end of induction (AML-MRC 10 protocol) and 4 underwent unpurged autologous, 2 allogeneic (from matched siblings) non-T-cell-depleted bone marrow transplantations (BMT) in first CR. One patient died due to allogeneic BMT-related complications, and 4 patients relapsed at 13, 17, 18, and 26 months. Only one patient achieved second CR. All relapsed patients died between 18 and 36 months with resistant disease (n = 3) or infection during salvage chemotherapy (n = 1). Two patients who had autologous BMT are alive and disease free at 44 and 50 months. Although statistical significance could not be shown, event-free survival and overall survival rates of AML1/ETO-positive patients (28.57 and 28.57%, respectively) at 3.5 years were even lower than those of AML1/ETO-negative patients. The results confirm some previous reports that AML1/ETO gene in children and adolescents is not a favorable prognostic factor.
authors.affiliation: Our Children Leukemia Foundation Hematology-Oncology and Bone Marrow Transplantation Unit, Medical Faculty of Istanbul, Turkey. Nazan_Sarper@hotmail.com
authors.forename: N
authors.initials: N
authors.lastname: Sarper
authors.forename: U
authors.initials: U
authors.lastname: Ozbek
authors.forename: L
authors.initials: L
authors.lastname: Ağaoğlu
authors.forename: U
authors.initials: U
authors.lastname: Ozgen
authors.forename: E
authors.initials: E
authors.lastname: Eryilmaz
authors.forename: N
authors.initials: N
authors.lastname: Yalman
authors.forename: S
authors.initials: S
authors.lastname: Anak
authors.forename: O
authors.initials: O
authors.lastname: Devecioğlu
authors.forename: G
authors.initials: G
authors.lastname: Gedikoğlu
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D050676:Core Binding Factor Alpha 2 Subunit; D018572:Disease-Free Survival; D005260:Female; D015870:Gene Expression; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000096:biosynthesis / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D000075142:RUNX1 Translocation Partner 1 Protein; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014157:Transcription Factors / Q000096:biosynthesis / Q000235:genetics*
chemical_list: C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D000075142:RUNX1 Translocation Partner 1 Protein; D014157:Transcription Factors